Brain insulin signalling in metabolic homeostasis and disease
T Scherer, K Sakamoto, C Buettner - Nature Reviews Endocrinology, 2021 - nature.com
Insulin signalling in the central nervous system regulates energy homeostasis by controlling
metabolism in several organs and by coordinating organ crosstalk. Studies performed in …
metabolism in several organs and by coordinating organ crosstalk. Studies performed in …
Management of individuals with diabetes at high risk for hypoglycemia: an endocrine society clinical practice guideline
AL McCall, DC Lieb, R Gianchandani… - The Journal of …, 2023 - academic.oup.com
Context Hypoglycemia in people with diabetes is common, especially in those taking
medications such as insulin and sulfonylureas (SU) that place them at higher risk …
medications such as insulin and sulfonylureas (SU) that place them at higher risk …
Factors affecting the absorption of subcutaneously administered insulin: effect on variability
AKJ Gradel, T Porsgaard, J Lykkesfeldt… - Journal of diabetes …, 2018 - Wiley Online Library
Variability in the effect of subcutaneously administered insulin represents a major challenge
in insulin therapy where precise dosing is required in order to achieve targeted glucose …
in insulin therapy where precise dosing is required in order to achieve targeted glucose …
Insulin‐associated weight gain in diabetes–causes, effects and coping strategies
D Russell‐Jones, R Khan - Diabetes, Obesity and Metabolism, 2007 - Wiley Online Library
Insulin therapy or intensification of insulin therapy commonly results in weight gain in both
type 1 and type 2 diabetes. This weight gain can be excessive, adversely affecting …
type 1 and type 2 diabetes. This weight gain can be excessive, adversely affecting …
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
Background Adding insulin to oral therapy in type 2 diabetes mellitus is customary when
glycemic control is suboptimal, though evidence supporting specific insulin regimens is …
glycemic control is suboptimal, though evidence supporting specific insulin regimens is …
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive …
K Hermansen, M Davies, T Derezinski… - Diabetes …, 2006 - Am Diabetes Assoc
OBJECTIVE—To assess efficacy and tolerability of insulin detemir or NPH insulin added to
oral therapy for type 2 diabetes in a treat-to-target titration protocol. RESEARCH DESIGN …
oral therapy for type 2 diabetes in a treat-to-target titration protocol. RESEARCH DESIGN …
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive …
Aims/hypothesis This 52-week multinational, randomised, open-label, parallel-group, non-
inferiority trial compared clinical outcomes following supplementation of oral glucose …
inferiority trial compared clinical outcomes following supplementation of oral glucose …
Psychological insulin resistance: patient beliefs and implications for diabetes management
M Brod, JH Kongsø, S Lessard, TL Christensen - Quality of Life Research, 2009 - Springer
Purpose To define and understand patient psychological insulin resistance (PIR) and its
impact on diabetes management. Methods Systematic literature review of peer-refereed …
impact on diabetes management. Methods Systematic literature review of peer-refereed …
Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis
SR Singh, F Ahmad, A Lal, C Yu, Z Bai, H Bennett - Cmaj, 2009 - Can Med Assoc
Background: Although insulin analogues are commonly prescribed for the management of
diabetes mellitus, there is uncertainty regarding their optimal use. We conducted meta …
diabetes mellitus, there is uncertainty regarding their optimal use. We conducted meta …
Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes
A Philis-Tsimikas, G Charpentier, P Clauson… - Clinical …, 2006 - Elsevier
BACKGROUND:: Many patients with poorly controlled type 2 diabetes mellitus (DM) receive,
as initial insulin treatment, the addition of a basal formulation to an existing regimen of oral …
as initial insulin treatment, the addition of a basal formulation to an existing regimen of oral …